banner
Home / News / US FDA to reconsider decision barring compounded versions of Lilly weight loss drug | Reuters
News

US FDA to reconsider decision barring compounded versions of Lilly weight loss drug | Reuters

Oct 15, 2024Oct 15, 2024

Sign up here.

Reporting By Brendan Pierson in New York; Editing by David Gregorio and Chris Reese

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Thomson Reuters

Brendan Pierson reports on product liability litigation and on all areas of health care law. He can be reached at [email protected].